Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Accounts receivable, gross by Quarter
Accounts receivable, gross (before chargeback allowances) ($M) ($M)
Moderna Accounts receivable, gross: $120M in Q2 2026, down 53.8% from a year earlier. That is the lowest of the 13 quarters on record here.
Latest, Q2 2026
120
Period ended Jun 30, 2026
Change on a year earlier
-53.8%
260 in Q2 2025
History
13 quarters
Since Q4 2022
Sources
12
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Accounts Receivable & GTN Reserves).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accounts receivable, gross (before chargeback allowances) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 120 | -53.8% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 203 | -18.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 368 | -47.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,024 | -25.9% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 260 | -47.2% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 249 | -41.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 698 | -55.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,732 | +15.8% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 492 | – | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 422 | – | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,584 | +14.4% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,360 | – | Form 10-Q (filed 2023-11-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,385 | – | Form 10-K (filed 2024-02-23) ↗ |
Cite this data
StockData. (2026). Moderna Accounts receivable, gross ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ar-gross
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.